BVF Partners TENX Position
Active3-Fund ConvergenceBVF Partners held their position in TENAX THERAPEUTICS, INC. (TENX) in Q4 2025, holding $4.1M worth of shares across 339,549 shares.
The position was first reported in Q3 2024 and has been tracked across 6 quarterly 13F filings.
TENX is a convergence signal: 3 specialist biotech funds hold this stock, suggesting high institutional conviction.
There is an upcoming Phase 3 readout for TNX-103 in 200 days (Oct 31, 2026), making the timing of BVF's position particularly relevant.
About TENAX THERAPEUTICS, INC.
Tenax Therapeutics, Inc., a specialty pharmaceutical company, engages in identifying, developing, and commercializing products for cardiovascular and pulmonary diseases in the United States and Canada. It develops TNX-103 and TNX-102 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of pulmonary arterial hypertension. The company was formerly known as Oxygen Biotherapeutics, Inc. and changed its name to Tenax Therapeutics, Inc. in September 2014. Tenax Therapeutics, Inc. was founded in 1967 and is headquartered in Morrisville, North Carolina.
Full company profile →Short Interest
0.9%
0.5 days to cover
BVF Partners TENX Position History
Frequently Asked Questions
Does BVF Partners own TENX?
Yes. As of Q4 2025, BVF Partners holds 339,549 shares of TENAX THERAPEUTICS, INC. (TENX) valued at $4.1M. This data comes from their SEC 13F filing.
How many hedge funds own TENX?
3 specialist biotech hedge funds currently hold TENX, including Perceptive Advisors, RTW Investments. When 3 or more specialist funds hold the same stock, BiotechEdge flags it as a convergence signal.
When did BVF Partners first buy TENX?
BVF Partners's position in TENX was first reported in Q3 2024. 13F filings are reported with a 45-day delay, so the actual purchase may have occurred earlier in the quarter.
Is BVF Partners's TENX position increasing or decreasing?
BVF Partners held their TENX position unchanged in the most recent quarter.
Get the weekly biotech signal briefing
Fund moves, convergence shifts, insider buys, and catalyst alerts — delivered free every Monday.
TENXCompany Page →
All fund holders, insider trades, catalysts, and cash runway
BVF PartnersPortfolio →
Full 13F holdings, sector breakdown, and top movers
Drill into any signal
Fund Convergence
See which stocks multiple specialist funds are buying at once
Catalyst Calendar
Every PDUFA date, Phase 3 readout, and AdCom in one view
Insider Trading
When executives buy their own stock — the strongest bullish signal
Cash Runway
Which biotechs are running low on cash and face dilution risk
Short Squeeze
High short interest + fund buying + upcoming catalyst = squeeze setup
Signal Rankings
Every signal in one composite score — ranked by conviction
Biotech Movers
Stocks with the most signal activity right now across all signals
13F Changes
What top biotech funds bought and sold in the latest 13F filing
Want AI context on every signal? Start free trial →